Praxsyn (OTCMKTS:PXYN) & InMed Pharmaceuticals (NASDAQ:INM) Critical Comparison

InMed Pharmaceuticals (NASDAQ:INM) and Praxsyn (OTCMKTS:PXYN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, valuation, dividends and risk.

Valuation and Earnings

This table compares InMed Pharmaceuticals and Praxsyn”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94 million	1.15	-$8.16 million	($2.89)	-0.59
Praxsyn	N/A	N/A	N/A	N/A	N/A

Praxsyn has lower revenue, but higher earnings than InMed Pharmaceuticals.

Analyst Ratings

This is a summary of current ratings and target prices for InMed Pharmaceuticals and Praxsyn, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1	0	0	0	1.00
Praxsyn	0	0	0	0	0.00

Given Praxsyn’s higher possible upside, analysts plainly believe Praxsyn is more favorable than InMed Pharmaceuticals.

Risk and Volatility

InMed Pharmaceuticals has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, Praxsyn has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500.

Institutional and Insider Ownership

20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 0.9% of InMed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares InMed Pharmaceuticals and Praxsyn’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
Praxsyn	N/A	N/A	N/A

Summary

Praxsyn beats InMed Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About InMed Pharmaceuticals

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company’s lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

About Praxsyn

Praxsyn Corporation, a health care company, provides medical practitioners with medications and services for their patients. It formulates non-narcotic and non-habit forming medications using therapeutic and preventative agents in the forms of transdermal creams, patches, and oral capsules for pain management, erectile dysfunction, and metabolic therapies. Praxsyn Corporation provides its products to patients covered under the California workers’ compensation system, as well as preferred provider contracts. The company was formerly known as The PAWS Pet Company, Inc. and changed its name to Praxsyn Corporation in March 2014. Praxsyn Corporation was founded in 2005 and is headquartered in Las Vegas, Nevada.